Mission Therapeutics
Generated by Meeveem AI
"Developing first-in-class therapeutics that target DUBs to treat Parkinson's and serious diseases"
Cambridge
•11 - 50 Employees
•Biotechnology
About Mission Therapeutics
Mission Therapeutics is a clinical stage biotech company developing first-in-class therapeutics that selectively inhibit deubiquitylating enzymes (DUBs). By enhancing mitophagy, the cellular process removing dysfunctional mitochondria, the company targets Parkinson's disease, heart failure, neurodegenerative disorders, and rare mitochondrial diseases. Lead candidates MTX325 and MTX652, both targeting USP30, are in clinical trials. Founded in 2011 and based in Cambridge, Mission has raised £117 million from investors including Pfizer and Roche. The company partners with AbbVie on Alzheimer's research and collaborates with the Michael J Fox Foundation and Oxford Parkinson's Disease Centre to translate science into transformative therapies.
14
Team Members
2011
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A world where cellular quality control is restored in patients with neurodegenerative and mitochondrial diseases, enabling healthier lives free from progressive decline.
Our Mission
At Mission Therapeutics, our mission is to transform the treatment of serious diseases by developing first-in-class therapeutics that enhance mitophagy through selective inhibition of disease-associated DUBs.